Navigation Links
Galderma announces approval for Differin gel 0.1 percent in Japan
Date:7/17/2008

ill co-promote Differin® Gel 0.1% with their respective sales forces and Shionogi will have sales and distribution rights for the product for a period of eight years. Commercialization will begin once the product is listed on the National Health Insurance reimbursement list, a process that is expected to be complete by autumn 2008.

"The decision by Japan's Ministry of Health, Labor and Welfare is excellent news for patients and physicians in Japan, who will now have access to a first-in-class topical retinoid for the treatment of acne," said Humberto C. Antunes, Chief Executive Officer of Galderma International. "We undertook the largest acne clinical program ever in Japan, and knew it would be a long journey to approval. This project underscores Galderma's commitment to dermatology in all parts of the world and dedication to improving the quality of life of acne patients in Japan."

Differin® Gel 0.1% is a naphthoic acid derivative with retinoid-like activities. Differin® will be the first product to be launched in Japan belonging to this class of treatment. Differin® appears to normalize the differentiation of a type of skin cell linked to acne, resulting in fewer non-inflammatory and inflammatory lesions.


'/>"/>

Contact: Dale Weiss
dale.weiss@galderma.com
817-961-5186
WeissComm Partners
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Galderma Completes Tender Offer for CollaGenex
2. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
3. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
4. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
5. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
6. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
7. Fresh Harvest Products, Inc. Announces New Brand Initiative
8. AMN Healthcare Announces Joint Commission Re-Certification
9. Peptimmune Announces the Second Close of Series D Private Financing
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Cornell makes cancer vaccine for clinical use 54990 1Cornell makes cancer vaccine for clinical use 54990 2Cornell makes cancer vaccine for clinical use 54990 3CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco 54987 1CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco 54987 2Increase in visceral fat during menopause linked with testosterone 9643 1Increase in visceral fat during menopause linked with testosterone 9643 2